Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 6/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515817 | 0.94 | LMNA (0.43) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4529223 | 0.91 | HKDC1 (0.40) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4514093 | 0.89 | TSHR (0.44) | NPC1LMNAALDH1A1TSHRCDK1 | |
| SCHEMBL4510793 | 0.87 | HKDC1 (0.39) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4522615 | 0.84 | HKDC1 (0.41) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4978987 | 0.84 | SMN1; SMN2 (0.37) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4515514 | 0.83 | TSHR (0.43) | NPC1LMNAALDH1A1TSHRCDK1 | |
| SCHEMBL4425849 | 0.83 | NPC1 (0.37) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4527001 | 0.82 | SMN1; SMN2 (0.36) | NPC1RAB9ALMNAHPGDALDH1A1 | |
| SCHEMBL4521631 | 0.81 | TSHR (0.37) | NPC1LMNAALDH1A1TSHRCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | NPC1 631/4885RAB9A 1675/4885LMNA 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.